Skip to main content

Mar Tintore Subirana

I am a Neurologist and Head of Care at the Centre d'Esclerosi Multiple de Catalunya (Cemcat) of the Neurology/Neuroimmunology service of the Vall d'Hebron University Hospital. Since June 2023 I have been Head of Section at the Centre d'Esclerosi Multiple de Catalunya (Cemcat) of the Neurology/Neuroimmunology service of the Vall d'Hebron University Hospital. Since 2021 I have been a professor of Neurology at the University of Vic-Central University of Catalonia (UVic-UCC).

Institutions of which they are part

Main researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca
Clinical neuroimmunology
General Hospital
Director
Multiple Sclerosis Centre of Catalonia

Mar Tintore Subirana

Institutions of which they are part

Main researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca
Clinical neuroimmunology
General Hospital
Director
Multiple Sclerosis Centre of Catalonia

I am a Neurologist and Head of Care at the Centre d'Esclerosi Multiple de Catalunya (Cemcat) of the Neurology/Neuroimmunology service of the Vall d'Hebron University Hospital. Since June 2023 I have been Head of Section at the Centre d'Esclerosi Multiple de Catalunya (Cemcat) of the Neurology/Neuroimmunology service of the Vall d'Hebron University Hospital. Since 2021 I have been a professor of Neurology at the University of Vic-Central University of Catalonia (UVic-UCC).

I have developed in particular the study of prognostic factors, multiple sclerosis of the child and adolescent, as well as family planning in women with multiple sclerosis. I am currently a member of the Advisory Ethics Committee (CEA) of the Vall d'Hebron University Hospital.

I have published more than 369 articles in national and international journals and am a regular reviewer of indexed journals both national and international. My factor H is currently 60 and until April 2026 my work has received 26,854 citations.

Projects

Papel de los factores hormonales relacionados con la mujer en el riesgo y pronóstico de la E.M.

IP: Mar Tintore Subirana
Collaborators: Susana Otero Romero, Jaume Sastre Garriga, Jordi Rio Izquierdo, Ingrid Galán Cartaña, Rosalia Horno Ocaña, Cristina Auger Acosta, Georgina Arrambide García, Alex Rovira Cañellas, Joaquin Castillo Justribo, Milagros Fraga Pereira
Funding agency: Instituto de Salud Carlos III
Funding: 98615
Reference: PI15/00170
Duration: 01/01/2016 - 31/12/2019

Diagnostic and prognostic biomarkers in pediatric multiple sclerosis and related demyelinating disorders

IP: Mar Tintore Subirana
Collaborators: Cristina Auger Acosta, Georgina Arrambide García, Alex Rovira Cañellas, Mireia Del Toro Riera, Angela Vidal Jordana, Luciana Midaglia Fernandez
Funding agency: Fundació La Marató de TV3
Funding: 100000
Reference: 20141831
Duration: 22/05/2015 - 22/11/2018

Las proteínas morfogenéticas óseas como posibles biomarcadores en la esclerosis múltiple: expresión en lesiones y líquido cefalorraquídeo de pacientes con esclerosis múltiple

IP: Carmen Espejo Ruiz
Collaborators: Herena Eixarch Ahufinger, Georgina Arrambide García, Mar Tintore Subirana, Elena Antima Martinez Saez
Funding agency: Fundación Merck Salud
Funding: 25000
Reference: SERONO-2013-04
Duration: 01/05/2014 - 01/11/2016

Aportaciones de la resonancia magnética de alto campo al estudio diagnóstico de pacientes con primeros brotes sugestivos de esclerosis múltiple

IP: Mar Tintore Subirana
Collaborators: Rosalia Horno Ocaña, Carmen Tur Gomez, Cristina Auger Acosta, Georgina Arrambide García, Elena Huerga Núñez, Joaquin Castillo Justribo, Mireia Castillo Juarez
Funding agency: Instituto de Salud Carlos III
Funding: 80465
Reference: PI12/01313
Duration: 01/01/2013 - 30/06/2016

Related news

A Vall d’Hebron study, carried out at Cemcat, shows that the risk of inflammatory activity increases after discontinuing treatment, but is considerably reduced in people over 60 years of age.

The project will analyse the functional activation of the NLRP3 inflammasome to advance the early identification of patients at risk of insufficient response to S1P receptor-modulating therapies.

Anti-Müllerian hormone had been proposed as a potential biomarker for predicting disease prognosis in women, but this study shows that the observed association is explained by patients’ chronological age.

Related professionals

Susana Anton Calvo

Susana Anton Calvo

Administration and Management
Liver Diseases
Read more
Laia Miquel Serra

Laia Miquel Serra

Postdoctoral researcher
Transfusional Medicine
Read more
Josep Sanjose Puig

Josep Sanjose Puig

Tècnic de recerca
Commercial and Academic Clinical Research
Read more
Silvia Ballester Esteve

Silvia Ballester Esteve

Research technician
Neuroradiology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.